FDA Package Insert NDA 021323 Background Material

FDA has released background material associated with NDA 021323, which concerns a package insert for a pharmaceutical product. The document was submitted through the FDA's pre-market approval process and is now accessible in the public docket on Regulations.gov.\n\nPharmaceutical manufacturers and regulatory affairs professionals should monitor this docket for additional FDA communications, review questions, or potential labeling requirements that may arise during the agency's evaluation of this NDA submission.